ClinicalTrials.gg
RecruitingNCT06980584ACCT-NOPHUpdated May 23, 2025

Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension

An interventional study of Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention and Pulmonary Vascular Interventional Therapy in Fibrosing Mediastinitis and Pulmonary Hypertension, sponsored by Beijing Chao Yang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Beijing Chao Yang Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.

Planned enrollment
38th of 47
48 · median 100
Started
2025
with 9 others
No phase
12 of 85
7 open now
Primary completion
2027-10
later than 21 of 35 live
Registered
72nd of 85
by date

Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 38th largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2025, is one of 12 with no phase, reaches primary completion later than 21 of the 35 other live ones, and was the 72nd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Hypertension, Pulmonary with a site in China, or all of them as a file.
02

Study summary

Through a randomized controlled trial (RCT) design, this study aiming to evaluated the efficacy and safety of rituximab lymph node injection combined with pulmonary vascular interventional therapy in treating fibrosing mediastinal pulmonary hypertension (FM-PH).Eligible participants were randomly assigned to either the combined treatment group, receiving both pulmonary vascular intervention and rituximab lymph node injection, or the interventional-only group, which received pulmonary vascular intervention alone. At 3, 6, and 12 months post-treatment, the efficacy was assessed based on symptom improvement, hemodynamic changes, lesion volume reduction, etc. Safety was mainly evaluated by comparing adverse event incidence between the two groups.

03

Conditions studied

  • Fibrosing Mediastinitis
  • Pulmonary Hypertension

Keywords

  • Rituximab
  • Endobronchial Ultrasound
  • Pulmonary Vascular Intervention
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with fibrosing mediastinitis between November 2024 and November 2026, aged between 18 and 85 years.
  2. The patient presented with symptoms of chest tightness, shortness of breath, and reduced exercise tolerance.
  3. Chest CT revealed mediastinal lymph node compression of the pulmonary artery, with evidence of pulmonary hypertension consistent with the patient's symptoms.
  4. The subject signed the form prior to participation and is able to comply with the study protocol and one-year follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Currently in the active phase of infection, including but not limited to tuberculosis, Histoplasma capsulatum, and Aspergillus infections;
  2. The underlying primary disease, such as sarcoidosis, Behcet's disease, or uncontrolled IgG4-related disease, is currently not well controlled.
  3. Before treatment, a large amount of pleural effusion was still present.
  4. Pulmonary function tests (PFT) showed \<30% of the predicted value, FEV1/FVC \<30%, and DLCO \<30%.
  5. There are to bronchoscopy or endovascular intervention.
  6. Complicated by other end-stage organ dysfunction, such as class C liver function or stage IV chronic renal failure.
  7. Complicated by severe .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Combined treatment group

    Participants assigned to this group will receive both pulmonary vascular intervention and rituximab lymph node injection.

    Procedure: Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention

  • Active comparator
    Interventional-only group

    Participants assigned to this group will receive pulmonary vascular intervention alone.

    Procedure: Pulmonary Vascular Interventional Therapy

Interventions

  • ProcedureRituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention

    Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy.

  • ProcedurePulmonary Vascular Interventional Therapy

    According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Six Minutes Walk Distance at 12 Months.

    Conduct 6-minute walk test to measure the 6-minute walk distance, and compare the walking distances at baseline and 12 months after treatment.

    Time frame: From enrollment to the end of treatment at 12 months

  2. The incidence of treatment-related serious adverse events (SAE)

    The incidence of treatment-related serious adverse events is measured by tracking and documenting any SAEs that occur during the treatment period, as well as through follow-up assessments. Each event is evaluated for severity and causality, and the incidence is calculated by dividing the number of patients who experience at least one treatment-related SAE by the total number of treated patients.

    Time frame: During the one-year follow-up period after treatment completion

Secondary outcomes

  1. Change from baseline in the World Health Organization Functional Classification of Pulmonary Hypertension at 3, 6 and 12 months.

    Change from Baseline in the World Health Organization Functional Classification of Pulmonary Hypertension (WHO-FC) which assessed based on clinical symptoms and signs at baseline and the end of treatment at 3, 6 and 12 months. The WHO-FC system consists of four levels: I, II, III, and IV. Higher levels indicate progressively more severe conditions.

    Time frame: From enrollment to the end of treatment at 3, 6 and 12 months.

  2. Change from Baseline in the mean pulmonary artery pressure (mPAP) at 3 and 12 Months.

    The mean pulmonary artery pressure (mPAP) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.

    Time frame: From enrollment to the end of treatment at 3 and12 months

  3. Change from Baseline in the Cardiac Index (CI) at 3 and 12 Months.

    The Cardiac Index (CI) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.

    Time frame: From enrollment to the end of treatment at 3 and12 months

  4. Change from Baseline in the Pulmonary Vascular Resistance (PVR) at 3 and 12 Months.

    The Pulmonary Vascular Resistance (PVR) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.

    Time frame: From enrollment to the end of treatment at 3 and12 months

  5. Change from Baseline in the forced vital capacity (FVC) at 3, 6 and 12 Months.

    Pulmonary function tests was performed, including the forced vital capacity (FVC), to evaluated pulmonary function at baseline and the end of treatment at 3, 6 and 12 Months.

    Time frame: From enrollment to the end of treatment at 3, 6 and 12 months

  6. Change from Baseline in the forced vital capacity of predicted (FVC%pred) at 3, 6 and 12 Months.

    Pulmonary function tests was performed, including the forced vital capacity of predicted (FVC%pred), to evaluated pulmonary function at baseline and the end of treatment at 3, 6 and 12 Months.

    Time frame: From enrollment to the end of treatment at 3, 6 and 12 months

  7. Change from Baseline in the forced expiratory volume in 1 second (FEV1) at 3, 6 and 12 Months.

    Pulmonary function tests was performed, including the forced expiratory volume in 1 second (FEV1), to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.

    Time frame: From enrollment to the end of treatment at 3, 6 and 12 months

  8. Change from Baseline in the forced expiratory volume in 1 second of predicted (FEV1%pred) at 3, 6 and 12 Months.

    Pulmonary function tests was performed, including the forced expiratory volume in 1 second of predicted (FEV1%pred), to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.

    Time frame: From enrollment to the end of treatment at 3, 6 and 12 months

  9. Change from Baseline in the FEV1/FVC ratio at 3, 6 and 12 Months.

    Pulmonary function tests was performed, including the FEV1/FVC ratio, to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.

    Time frame: From enrollment to the end of treatment at 3, 6 and 12 months

  10. Change of the BNP/NT-Pro BNP from baseline to the end of treatment at 3, 6 and 12 months.

    The BNP/NT-Pro BNP will be measured at baseline the end of treatment at 3, 6 and 12 months to evaluate the condition of heart failure.

    Time frame: From enrollment to the end of treatment at 3, 6 and 12 months.

  11. The restenosis rate of blood vessels after interventional therapy at the end of treatment at 3 and 12 months

    Restenosis following interventional therapy was monitored at the end of treatment at 3 and 12 months, with restenosis defined as a blood vessel diameter reduction of more than 50% from the original size, or when the pressure gradient (Pd) at the site of vascular stenosis increases by 5 mmHg or more compared to the last measurement.

    Time frame: From enrollment to the end of treatment at 3 and 12 months.

  12. Change of the mediastinal lesion volume from baseline to 3 and 12 months after the end of treatment.

    The mediastinal lesion volume will be measured at baseline and 3, 12 months after the end of treatment using CTPA or PET-CT imaging. The volume is represented by the maximum transverse diameter of the cross-section of the lesion site.

    Time frame: From enrollment to the end of treatment at 3 and12 months.

  13. Change from baseline of the quality-of-life score at 3, 6 and 12 months after the end of treatment.

    Quality of life was assessed using the 36-Item Short-Form Health Survey (SF-36) at baseline and 3, 6 and 12 months after the end of treatment. The SF-36 scoring scale consists of 8 dimensions, which can be summarized as physical health and mental health. The score range of each dimension is 0 to 100 points. The higher the score, the better the health condition.

    Time frame: From enrollment to the end of treatment at 3, 6 and 12 months

  14. Number of participants with complications of bronchoscopy and pulmonary intervention.

    Measure the probability of complications occurring during or after therapeutic operations. Complications of pulmonary vascular intervention include pulmonary vascular injury, arrhythmia, reperfusion pulmonary edema, etc; Complications of bronchoscopy include pneumothorax, massive hemoptysis, infection, etc.

    Time frame: Immediately or in the short term after treatment, and within 12 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Jia M, Su H, Jiang K, Wang A, Guo Z, Zhu H, Zhang F, Sun X, Shi Y, Pan X, Cao Y. Incidence and predictors of in-stent restenosis following intervention for pulmonary vein stenosis due to fibrosing mediastinitis. Orphanet J Rare Dis. 2024 Oct 14;19(1):379. doi: 10.1186/s13023-024-03391-8. PubMed 39397011 ↗
  • Varghese C, Johnson GB, Eiken PW, Edell ES, Specks U, Larson NB, Peikert T. A Retrospective Evaluation of the Treatment Effects of Rituximab in Patients with Progressive and Symptomatic Fibrosing Mediastinitis. Ann Am Thorac Soc. 2024 Nov;21(11):1533-1541. doi: 10.1513/AnnalsATS.202405-533OC. PubMed 39106522 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Oct 2027, 32 months after the start.

Of 135 non-industry interventional studies with no phase under Hypertension, Pulmonary, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's planned 32 months is above that.

Counting every sponsor, half of 150 studies reached it within 23 months; a quarter within 9 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2025
First posted
May 20, 2025
StartActual
Feb 10, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06980584
Collaborators
Beijing Municipal Health Commission
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Feb 10, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
May 23, 2025

Study contacts

Juanni Gong, Doctor of Medicine
Contact
juannigong2018@126.com
15801511482

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion